Better Heart Health. Delivered.
To empower patients to lead healthier lives by harnessing the power of red blood cells to deliver precision medicine for better lipid management.
Market Need
By 2030, more than 65% of US population is estimated to be adults with cardiovascular burden requiring healthcare expenses of over $800 billion. Annual expenses for one high-risk ASCVD patient is expected to be $50,000.
Our addressable market is greater than two million high-risk ASCVD patients in the US.
Science and Technology
We have a small molecule agent with a unique combination of mechanisms to provide for a robust decrease in plasma LDL-C and Lp(a). Our red cell delivery technology is intended to provide for a long duration of action (monthly or less frequent) in high-risk ASCVD patients on maximally tolerated lipid lowering therapies.